BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Luo B, Zhang Y, Zhang C, Liu X, Shi C. Intestinal microbiota: A potential target for enhancing the antitumor efficacy and reducing the toxicity of immune checkpoint inhibitors. Cancer Lett 2021;509:53-62. [PMID: 33845122 DOI: 10.1016/j.canlet.2021.04.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Li M, Liu B, Li R, Yang P, Leng P, Huang Y. Exploration of the link between gut microbiota and purinergic signalling. Purinergic Signal 2022. [PMID: 36121551 DOI: 10.1007/s11302-022-09891-1] [Reference Citation Analysis]
2 Wu L, Bao F, Li L, Yin X, Hua Z. Bacterially mediated drug delivery and therapeutics: strategies and advancements. Adv Drug Deliv Rev 2022;:114363. [PMID: 35649449 DOI: 10.1016/j.addr.2022.114363] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
3 Huang X, Mu N, Ding Y, Lam HW, Yue L, Gao C, Chen T, Yuan Z, Wang R. Targeted delivery and enhanced uptake of chemo-photodynamic nanomedicine for melanoma treatment. Acta Biomater 2022:S1742-7061(22)00284-7. [PMID: 35577046 DOI: 10.1016/j.actbio.2022.05.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Li Y, Guo R. Durvalumab as Consolidation Therapy in Post-Multimodal Interventional Treatment for Patients with Advanced Solid Tumors: A Preliminary Study. J Oncol 2022;2022:7794840. [PMID: 35342409 DOI: 10.1155/2022/7794840] [Reference Citation Analysis]
5 Kotulová J, Hajdúch M, Džubák P. Current Adenosinergic Therapies: What Do Cancer Cells Stand to Gain and Lose? Int J Mol Sci 2021;22:12569. [PMID: 34830449 DOI: 10.3390/ijms222212569] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
6 Qin BD, Jiao XD, Zhou XC, Shi B, Wang J, Liu K, Wu Y, Ling Y, Zang YS. Effects of concomitant proton pump inhibitor use on immune checkpoint inhibitor efficacy among patients with advanced cancer. Oncoimmunology 2021;10:1929727. [PMID: 34350061 DOI: 10.1080/2162402X.2021.1929727] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 13.0] [Reference Citation Analysis]